MRI pinpoints prostate cancer recurrence for precision radiation boost

NCT ID NCT01411345

Ongoing Disease control Sponsor: University of Miami Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase II trial tests whether using MRI to map the exact location of recurrent prostate cancer after prostatectomy allows doctors to safely deliver a higher radiation dose to the tumor while sparing healthy tissue. The study enrolled 37 men whose PSA levels rose after surgery. The goal is to see if this targeted approach improves PSA response rates and reduces anxiety compared to standard radiation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radiation therapy
What this could lead to: If successful, this approach could improve control of prostate cancer recurrence after surgery by targeting higher radiation doses to tumor areas seen on MRI.
What could go wrong: This is a small, early-phase trial with only 37 participants, so results may not apply broadly. Higher radiation doses also carry increased risk of side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE ADENOCARCINOMA PROSTATE CANCER

Contacts and locations

Locations

University of Miami

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.